Guilin Sanjin said in an online briefing that Sanjin Granules, a key product the
company is prioritizing, has seen rapid sales growth but its revenue base
remains small and its contribution to total volumes is not yet material;
achieving scale will take time. The company will accelerate hospital-channel
sales to try to bring the product to scale sooner.
